These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 16329642)

  • 1. [Cost-effect pharmacological studies of Parkinson's disease].
    Chikina ES; Belousov IuB
    Zh Nevrol Psikhiatr Im S S Korsakova; 2005; 105(11):68-72. PubMed ID: 16329642
    [No Abstract]   [Full Text] [Related]  

  • 2. Antiparkinson drug adherence and its association with health care utilization and economic outcomes in a Medicare Part D population.
    Wei YJ; Palumbo FB; Simoni-Wastila L; Shulman LM; Stuart B; Beardsley R; Brown CH
    Value Health; 2014 Mar; 17(2):196-204. PubMed ID: 24636377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Flexibility of Markov modeling for clinical pharmacoeconomics: illustration for cost-effectiveness in early Parkinson's disease.
    Postma MJ; Boersma C
    Expert Rev Clin Pharmacol; 2012 Jan; 5(1):1-4. PubMed ID: 22142151
    [No Abstract]   [Full Text] [Related]  

  • 4. Costs of Parkinson's disease and antiparkinsonian pharmacotherapy: an Italian cohort study.
    Winter Y; von Campenhausen S; Reese JP; Balzer-Geldsetzer M; Longo K; Spiga G; Boetzel K; Eggert K; Oertel WH; Dodel R; Barone P
    Neurodegener Dis; 2010; 7(6):365-72. PubMed ID: 20523028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Implication of piribedil (pronoran) in the treatment of Parkinson's disease; a clinical and pharmacoeconomic analysis].
    Mil'chakova AE; Popov GR; Bykov AV; Gekht AB
    Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(4):49-55. PubMed ID: 18567194
    [No Abstract]   [Full Text] [Related]  

  • 6. Re: Cabergoline versus levodopa monotherapy: a decision analysis.
    Marras C
    Mov Disord; 2004 Jun; 19(6):736. PubMed ID: 15197726
    [No Abstract]   [Full Text] [Related]  

  • 7. Estimating the direct and indirect costs associated with Parkinson's disease.
    Rodríguez-Blázquez C; Forjaz MJ; Lizán L; Paz S; Martínez-Martín P
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(6):889-911. PubMed ID: 26511768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost effectiveness of pharmacotherapies in early Parkinson's disease.
    Eggert KM; Reese JP; Oertel WH; Dodel R
    CNS Drugs; 2008; 22(10):841-60. PubMed ID: 18788836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The economic evaluation of pharmacotherapies for Parkinson's disease.
    Coyle D; Barbeau M; Guttman M; Baladi JF
    Parkinsonism Relat Disord; 2003 Jun; 9(5):301-7. PubMed ID: 12781598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prevalence and main methods of treatment of advanced stages of Parkinson's disease].
    Seliverstov IuA; Illarioshkin SN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(11):100-6. PubMed ID: 24479164
    [No Abstract]   [Full Text] [Related]  

  • 11. [The clinical-pharmacoeconomic study of efficacy of stalevo in the treatment of Parkinson's disease with motor fluctuations].
    Levin OS; Smolentseva IG; Fedorova NV; Chigir' IP; Dokadina LV; Makhnev SO
    Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(7):27-34. PubMed ID: 18833115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cabergoline versus levodopa monotherapy.
    Wheatley K; Clarke CE; Ives N; Gray R
    Mov Disord; 2004 Jun; 19(6):733-4; author reply 734-5. PubMed ID: 15197724
    [No Abstract]   [Full Text] [Related]  

  • 13. Cost analysis of unilateral and bilateral pallidotomy for Parkinson's disease.
    Green AL; Joint C; Sethi H; Bain P; Aziz TZ
    J Clin Neurosci; 2004 Nov; 11(8):829-34. PubMed ID: 15519857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of Parkinson's disease.
    McFarland HR
    Neurology; 1993 May; 43(5):1056-7. PubMed ID: 8347192
    [No Abstract]   [Full Text] [Related]  

  • 15. [Parkinson's disease: cost-of-illness in an outpatient cohort].
    Reese JP; Winter Y; Balzer-Geldsetzer M; Bötzel K; Eggert K; Oertel WH; Dodel R; Campenhausen Sv
    Gesundheitswesen; 2011 Jan; 73(1):22-9. PubMed ID: 20229454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of entacapone in Parkinson's disease: a Markov process analysis.
    Nuijten MJ; van Iperen P; Palmer C; van Hilten BJ; Snyder E
    Value Health; 2001; 4(4):316-28. PubMed ID: 11705299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Costs of illness and care in Parkinson's disease: an evaluation in six countries.
    von Campenhausen S; Winter Y; Rodrigues e Silva A; Sampaio C; Ruzicka E; Barone P; Poewe W; Guekht A; Mateus C; Pfeiffer KP; Berger K; Skoupa J; Bötzel K; Geiger-Gritsch S; Siebert U; Balzer-Geldsetzer M; Oertel WH; Dodel R; Reese JP
    Eur Neuropsychopharmacol; 2011 Feb; 21(2):180-91. PubMed ID: 20888737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The prevalence and pharmacological cost of Parkinson's disease in Spain].
    Abasolo-Osinaga E; Abecia-Inchaurregui LC; Fernández-Díaz E; Barcenilla-Laguna A; Bañares-Onraita T
    Rev Neurol; 2006 Dec 1-15; 43(11):641-5. PubMed ID: 17133323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Entacapone: adjunctive use in patients with advanced Parkinson's disease.
    McAuley L
    Issues Emerg Health Technol; 2000 Dec; (12):1-7. PubMed ID: 11902220
    [No Abstract]   [Full Text] [Related]  

  • 20. Pramipexole in the treatment of Parkinson's disease: new developments.
    Möller JC; Oertel WH
    Expert Rev Neurother; 2005 Sep; 5(5):581-6. PubMed ID: 16162081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.